slides · global inventory
Problem Statement Canvas
Tool collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 2,665
Current window 1,951-1,980
Pages 89
Rows per page 30
Tool
1,951-1,980 of 2,665
07
The diagram shows a circular, inefficient optimization process (affinity, developability, toxicity) leading to suboptimal candidates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
08
The slide uses a comparison frame to contrast small molecule data availability with biologic data scarcity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
03
Uses a rhetorical question to frame the company's value proposition as a paradigm shift.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The chart uses a 'Today' marker to emphasize the rapid growth phase.Astra | Investor Presentation Deck | 22 slides · Astra
Pitch deck Investor relations Beat · Problem1 hit
08
The slide uses a comparison to erectile dysfunction to frame the market opportunity.Dare Bioscience | Investor Presentation Deck | 26 slides · Daré Bioscience
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM despite success in other indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
27
Eutelsat | Investor Presentation Deck | 70 slidesEutelsat | Investor Presentation Deck | 70 slides · Eutelsat
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
07
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
59
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
21
The slide uses a hierarchical clustering heatmap to demonstrate patient-specific drug responses.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide displays a heatmap of 43 patient samples showing ABS scores, signature scores, and cancer diagnoses.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
42
The slide uses a small multiples approach to show dose-response curves across 10 patient samples, then aggregates them into two groups to highlight differential sensitivity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
63
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide uses a hierarchical clustering heatmap to visualize drug sensitivity across patient samples.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
65
Scientific/medical context slide explaining a therapeutic target.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
09
Includes a clinical imaging case study (A-D) showing patient response over time.Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides · Fusion Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
03
The slide uses a circular central graphic to anchor the list of pain points.Hyperfine | Investor Presentation Deck | 16 slides · Hyperfine
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
This is a classic 'problem-solution' framing slide.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
12
The slide uses a process flow diagram to connect cellular pathology to clinical symptoms in the heart, liver, and kidneys.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
35
The slide uses a complex biological pathway diagram to illustrate the mechanism of action and the problem of redundant signaling pathways.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
05
The slide uses a product photo to demonstrate the scale and form factor of the device.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
07
Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a numbered list format to categorize the problem into four distinct areas: clinical outcomes, cost/length of stay, reimbursement losses, and readmission penalties.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations Beat · Problem1 hit
11
Uses a 'Misconception vs. Real Issue' framework to pivot the narrative.VinFast | Investor Presentation Deck | 29 slides · VinFast
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit